{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-052165","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.011292+00:00","generated_at":"2026-05-15T01:04:35.064105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending","bullets":["Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.","GAAP diluted EPS $0.55, Adjusted diluted EPS $0.71; Adjusted EBITDA $415M (28.4% margin).","Board declares quarterly dividend of $0.02/share, payable June 11 to holders of record May 11.","Pending all-cash merger with Sun Pharma expected to close early 2027; guidance and earnings calls suspended.","Net income $146M vs $87M YoY; cash and equivalents $1.12B, debt $8.57B."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-052165","json":"https://secwatch.observer/filing/0001104659-26-052165.json","markdown":"https://secwatch.observer/filing/0001104659-26-052165.md","text":"https://secwatch.observer/filing/0001104659-26-052165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:04:35.064105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f7bc8b5cb1834fea6151a250f6d78e41381d2a8","claim":"Organon & Co. reported quarter ended March 31, 2026 results: revenue $1.460 billion, net income $146 million, EPS $0.55.","evidence_excerpt":"Organon Reports Results for the First Quarter Ended March 31, 2026 · First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. · First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. · First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.460 billion"},{"label":"Net income","value":"$146 million"},{"label":"EPS","value":"$0.55"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}